Quinagolide : a valuable treatment option for hyperprolactinaemiaBARLIER, Anne; JAQUET, Philippe.European journal of endocrinology. 2006, Vol 154, Num 2, pp 187-195, issn 0804-4643, 9 p.Article

Current treatment issues in female hyperprolactinaemiaCROSIGNANI, Pier Giorgio.European journal of obstetrics, gynecology, and reproductive biology. 2006, Vol 125, Num 2, pp 152-164, issn 0301-2115, 13 p.Article

An investigation of the effectiveness of testosterone implants in combination with the prolactin inhibitor quinagolide in the suppression of spermatogenesis in menHAIR, W. Morton; WU, Frederick C. W; LINCOLN, Gerald A et al.Human reproduction (Oxford. Print). 2003, Vol 18, Num 4, pp 749-755, issn 0268-1161, 7 p.Article

QuinagolideLa Revue Prescrire. 1997, Vol 17, Num 171, pp 162-164, issn 0247-7750Article

Spectrophotometric determination of clobetasol propionate, halobetasol propionate, quinagolide hydrochloride, through charge transfer complexationMOSTAFA, Azza A; BEBAWY, Lories I; REFAAT, Heba H et al.Journal of pharmaceutical and biomedical analysis. 2002, Vol 27, Num 6, pp 889-899, issn 0731-7085Article

Dopamine agonist therapy in hyperprolactinemiaWEBSTER, J.Journal of reproductive medicine. Supplement. 1999, Vol 44, Num 12, pp 1105-1110Article

Traitement des macroprolactinomes par le quinagolide (Norprolac®) = Treatment of prolactin-secreting pituitary macroadenomas with quinagolide (Norprolac®)TABARIN, A; CATARGI, B.Annales d'endocrinologie. 1997, Vol 58, Num 2, pp 87-94, issn 0003-4266Article

The non-ergot derived dopamine agonist quinagolide in prevention of early ovarian hyperstimulation syndrome in IVF patients: a randomized, double-blind, placebo-controlled trialBUSSO, Cristiano; FERNANDEZ-SANCHEZ, Manuel; GARCIA-VELASCO, Juan Antonio et al.Human reproduction (Oxford. Print). 2010, Vol 25, Num 4, pp 995-1004, issn 0268-1161, 10 p.Article

Efficacy of quinagolide in resistance to ergot dopamine agonists : results of a multicenter studyROHMER, V; FRENEAU, E; MORANGE, I et al.Annales d'endocrinologie. 2000, Vol 61, Num 5, pp 411-417, issn 0003-4266Conference Paper

Macroprolactinoma shrinkage during cabergoline treatment is greater in naive patients than in patients pretreated with other dopamine agonists : A prospective study in 110 patientsCOLAO, A; DI SARNO, A; LOMBARDI, G et al.The Journal of clinical endocrinology and metabolism. 2000, Vol 85, Num 6, pp 2247-2252, issn 0021-972XArticle

Prolactine, hyperprolactinémies et inhibiteurs de la prolactine = Prolactin, hyperprolactinemas and prolactin inhibitorsSTEILER, V; BONNEAUX, F; LABRUDE, P et al.Lyon pharmaceutique. 1998, Vol 49, Num 3, pp 159-166, issn 0024-7804Article

MR imaging of pituitary adenomas treated with the prolactin inhibitor quinagolideILKKO, E; TIKKAKOSKI, T; SALMELA, P et al.Acta radiologica (1987). 2002, Vol 43, Num 2, pp 125-129, issn 0284-1851Article

The effect of quinagolide and cabergoline, two selective dopamine receptor type 2 agonists, in the treatment of prolactinomasDI SARNO, A; LANDI, M. L; MARZULLO, P et al.Clinical endocrinology (Oxford. Print). 2000, Vol 53, Num 1, pp 53-60, issn 0300-0664Article

Prolactinomas resistant to standard dopamine agonists respond to chronic cabergoline treatmentCOLAO, A; DI SARNO, A; SARNACCHIARO, F et al.The Journal of clinical endocrinology and metabolism. 1997, Vol 82, Num 3, pp 876-883, issn 0021-972XArticle

Hormone levels and tumour size response to quinagolide and cabergoline in patients with prolactin-secreting and clinically non-functioning pituitary adenomas : predictive value of pituitary scintigraphy with ¹²³I-methoxybenzamideCOLAO, A; FERONE, D; LASTORIA, S et al.Clinical endocrinology (Oxford. Print). 2000, Vol 52, Num 4, pp 437-445, issn 0300-0664Article

Prolactin decrease and shift to a normal-like isoform profile during treatment with quinagolide in a patient affected by an invasive prolactinomaGUIDE, R; VALENTI, S; FOPPIANI, L et al.Journal of endocrinological investigation (Testo stampato). 1997, Vol 20, Num 5, pp 289-293, issn 0391-4097Article

Benign intracranial hypertension associated with the withdrawal of a non-ergot dopamine agonistATKIN, S. L; MASSON, E. A; BLUMHARDT, L. D et al.Journal of neurology, neurosurgery and psychiatry. 1994, Vol 57, Num 3, pp 371-372, issn 0022-3050Conference Paper

Treatment of macroprolactinoma with the new potent non-ergot D₂-dopamine agonist quinagolide and effects on prolactin levels, pituitary function, and the renin-aldosterone system : results of a clinical long-term studyNICKELSEN, T; JUNGMANN, E; ALTHOFF, P et al.Arzneimittel-Forschung. 1993, Vol 43, Num 4, pp 421-425, issn 0004-4172Article

Effects of hyperprolactinemia treatment with the dopamine agonist quinagolide on endometriotic lesions in patients with endometriosis-associated hyperprolactinemiaGOMEZ, Raul; ABAD, Antonio; DELGADO, Francisco et al.Fertility and sterility. 2011, Vol 95, Num 3, pp 882-888, issn 0015-0282, 7 p.Article

Correlation of scintigraphic results using ¹²³I-methoxybenzamide with hormone levels and tumor size response to quinagolide in patients with pituitary adenomasFERONE, D; LASTORIA, S; COLAO, A et al.The Journal of clinical endocrinology and metabolism. 1998, Vol 83, Num 1, pp 248-252, issn 0021-972XArticle

Bone marker and bone density responses to dopamine agonist therapy in hyperprolactinemic malesDI SOMMA, C; COLAO, A; DI SARNO, A et al.The Journal of clinical endocrinology and metabolism. 1998, Vol 83, Num 3, pp 807-813, issn 0021-972XArticle

In vivo and in vitro effects of octreotide, quinagolide and cabergoline in four hyperprolactinaemic acromegalics : Correlation with somatostatin and dopamine D₂ receptor scintigraphyFERONE, Diego; PIVONELLO, Rosario; LASTORIA, Secondo et al.Clinical endocrinology (Oxford. Print). 2001, Vol 54, Num 4, pp 469-477, issn 0300-0664Article

A cross-over study with the two novel dopaminergic drugs cabergoline and quinagolide in hyperprolactinemic patientsGIUSTI, M; PORCELLA, E; CARRARO, A et al.Journal of endocrinological investigation (Testo stampato). 1994, Vol 17, Num 1, pp 51-57, issn 0391-4097Article

Acute and long-term effects of once-daily oral bromocriptine and a new long-acting non-ergot dopamine agonist, quinagolide, in the treatment of hyperprolactinemia : a double-blind studyVERHELST, J. A; FROUD, A. L; TOUZEL, R et al.Acta endocrinologica (Oslo). 1991, Vol 125, Num 4, pp 385-391, issn 0001-5598Article

A comparative review of the tolerability profiles of dopamine agonists in the treatment of hyperprolactinaemia and inhibition of lactationWEBSTER, J.Drug safety. 1996, Vol 14, Num 4, pp 228-238, issn 0114-5916Article